ClinicalTrials.gg
Not yet recruitingNCT07850648CAN-EXACTUpdated Oct 5, 2026

The CANadian EXAcerbation of COPD Trial

An observational study in COPD and AECOPD, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Not yet recruiting at 1 site in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Observational

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · McGill University Health Centre/Research Institute of the McGill University Health Centre.

Started
2026
the only one that year
Observational
6 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the only one that started in 2026, is one of 6 observational ones, and was the 14th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, or all of them as a file.
02

Study summary

The natural history of Chronic Obstructive Pulmonary Disease (COPD) is marked by acute, episodic attacks known as exacerbations of COPD. These events are associated with increased systemic inflammation, lung function decline, hospitalization, and mortality. Despite their high clinical burden, the mechanisms underlying exacerbations, as well as effective approaches to their diagnosis, monitoring, and treatment, represent important unmet clinical care gaps.

CAN-EXACT is a prospective longitudinal observational cohort consisting of patient participants with moderate, severe, and very severe COPD with a history of frequent exacerbations. Participants undergo detailed clinical, physiological, imaging, and biological assessments at baseline and at a two-year follow-up visit. Every two weeks, participants complete self-reported symptom and exacerbation questionnaires and continuously wear a biometric wristband to remotely monitor respiratory, cardiac, sleep, physical activity, and autonomic parameters. When participants experience an exacerbation requiring in-person unscheduled acute care, several bedside tests and procedures are performed on each occasion. Biological samples, collected both at the baseline and the follow-up study visits as well as during each acute exacerbation requiring in-person care, are analyzed and are then transferred to a biobank.

This overall cohort design allows for both the comprehensive phenotyping of baseline clinical risk factors as well as for the deep phenotyping of each individual acute event.

Read the detailed description

The objective of the CAN-EXACT prospective observational cohort study is to collect multidimensional data along both chronic and acute phases of the disease in order to generate new evidence on the underlying mechanisms, diagnosis, monitoring and treatment of acute exacerbations, and thereby advance the standard of care in COPD.

The investigators hypothesize that CAN-EXACT will generate novel insights that will help fill and address the pressing knowledge gaps and unmet needs pertaining to exacerbations of COPD.

03

Conditions studied

  • COPD
  • AECOPD

Keywords

  • acute exacerbation of COPD (AECOPD)
  • chronic obstructive pulmonary disease (COPD)
  • remote patient monitoring
  • oscillometry
  • heart-lung interactions
  • type 2 inflammation
  • infection
  • imaging biomarkers
  • clinical exercise testing
  • patient-reported outcomes
  • biobank
  • ambient air pollution
  • mechanism
  • immunology
  • health economic evaluation
  • non-type 2 inflammation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be recruited from respiratory clinics and urgent care settings at the McGill University Health Centre, Montreal, Quebec, Canada. Potential participants will be asked by their treating clinical team if they can be contacted for possible participation in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged ≥40 years
  • Former or current smoker with a ≥10 pack-year history, or with a confirmed history of alpha-1 antitrypsin deficiency
  • Spirometry-confirmed (/FVC \< 0.7) and FEV1 \< 80% of predicted
  • History of ≥2 COPD exacerbations in the past 12 months requiring systemic , antibiotics, or both
  • Capacity to access internet at regular intervals

Exclusion criteria

Exclusion Criteria:

  • Inability to provide or to participate in study procedures
  • Any life-threatening condition, including but not limited to , that in the opinion of the investigator might prevent the participant from completing study visits
  • Currently being treated for an exacerbation and in the opinion of the investigator might be unable to complete study visits representative of the participant's clinical baseline
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. COPD Exacerbations

    COPD exacerbations, acute events with symptom worsening and characterized by increased dyspnea and/or cough and sputum that is often associated with increased local and systemic inflammation, will be ascertained through biweekly participant-reported questionnaires and medical records. Exacerbations represent the primary outcome of CAN-EXACT and will be summarized as the rate per participant-year and will be classified by severity.

    Time frame: Baseline to 24 months

  2. Diagnostic Markers of COPD Exacerbations

    Markers for the diagnosis, monitoring and prediction of COPD exacerbations, derived from clinical assessment, point-of-care testing, patient-reported outcomes, and continuous remote monitoring.

    Time frame: Baseline to 24 months

Secondary outcomes

  1. Risk Factors Associated with COPD Exacerbations

    Identifiable clinical, physiological, and environmental factors associated with exacerbation occurrence and frequency.

    Time frame: Baseline to 24 months

  2. Current and Emerging COPD Exacerbation Interventions

    Efficacy of the various observed interventions and healthcare resources used to treat exacerbations.

    Time frame: Baseline to 24 months

  3. Mortality

    Mortality (death) over the follow-up period, confirmed by chart review.

    Time frame: Baseline to 24 months

  4. Health Economic Impact of COPD Exacerbations

    Costs associated with exacerbations and with the various health care interventions and resources used to treat them.

    Time frame: Baseline to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Due to data privacy regulations, individual participant data collected during this study is not publicly accessible. However, access to anonymized data may be granted upon evaluation by the trial management group. Additional documents will also be available upon inquiry. All requests should be directed to the corresponding author (BAR).

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 24 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Sep 28, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 added
What changed in the outcomes
  • AddedMortalityTime frame: Baseline to 24 months
Oct 5, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 5, 2026
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedMortalityTime frame: Baseline to 24 months
    + 1 other change: description
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850648
Collaborators
DiaSorin Inc.
Responsible party
Bryan A. Ross (Clinician-Scientist (RI-MUHC), Respirologist (MUHC), Assistant Professor (McGill University), McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 28, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Bryan A. Ross, MD, MSc (Physiol), MSc (Epi)
Contact
bryan.ross@mcgill.ca
(514) 843-1465

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion